CPhI Online is the largest global marketplace in the pharma ingredients industry
Pipelines, Economics and IP: How Bioprocessing Tech Firms Assess Markets
Identifying areas of unmet need to guide R&D strategy and shape drug pipelines
Epidemiology is a core skill for biopharmaceutical companies. Being able to identify an area of unmet medical need helps guide R&D strategy and, ultimately, is what shapes drug pipelines. It is also an important metric for bioprocessing technology suppliers. For such companies, disease monitoring is one of multiple factors used in sales forecasting and resource allocation.
Conor McKechnie, Chief Marketing Officer, GE Healthcare Life Sciences told us, “Modelling and predicting market demand for our current, planned and future products and services, is complex. “Given the subsequent business strategy and capital allocation decisions, GE Life Sciences uses a very broad and constantly evolving series of data sources.”
GE does not disclose specific details of how it monitors markets, however, McKechnie confirmed that epidemiology is taken into consideration along with a number of other factors.“These [GE’s market analysis metrics] include anything from macro socio-economic trends, disease epidemiology, national and transnational governmental investment strategies.”
He added that related metrics such as emerging areas of medical research as well as things venture capital activity, Government support for research and customer intelligence are also factored into decision making. “Combining this myriad of constantly changing data and insight with, most importantly, a very clear understanding of our customers’ needs helps us reach the best decisions for our customers and our business.”
Biopharmaceutical product pipelines are also an important consideration when assessing markets according to Karen Tiano, company spokesperson, at the Life Science business of Merck.
“We have a multi-step process. We look at the drug pipeline to understand what drugs are coming online, and we look at the commercial and development success — how they get to market, and once they get there, what the uptake is. At that point, we know roughly what the big molecules are.
She added that, “We have an internal model to figure out how much demand that actually means in terms of volume of drugs being manufactured. We then determine the specific demands for us for different types of products, whether it be consumables, instruments, systems or services in order to supply them.”
Looking at drug pipelines and products rather than clinical research is appropriate for the bioprocessing sector says Eric Langer, BioPlan Associates’ president and managing partner.
“Since single use systems (SUS) and bioprocessing devices are really not able to affect clinical outcomes – for example an RA biologic could be manufactured with the same equipment as a cancer therapeutic - these companies probably monitor the pipeline more than which clinical area is growing vs others.
He also told us that, “Monitoring pipeline could be an indication of future demand for alternative technologies. Similarly, biosimilars in the pipeline can be monitored, but these are more commercial decisions rather than directly bioprocessing-related.”
Bioprocessing technology suppliers also take IP laws into consideration before deciding how they will approach a market according to Dr Ross Cummings, senior associate patent attorney at Gill, Jennings & Every LLP.
He told us, “The IP landscape is certainly something that any technology company looking to enter a market should be aware of. This can most obviously help avoid stepping on others’ toes by identifying others’ rights and assessing the risk of infringing such rights. “This can also be a useful exercise to assess the state of the art and identify potential competitors, partners and suppliers” Cummings said.
Keep pace with developments in Bioprocessing
Each year the CPhI brand unites more than 100,000 pharmaceutical professionals through exhibitions, conferences and online communities. If you're looking to meet the leading manufacturers and developers in the Bioprocessing space, learn the latest developments through quality conferences and access unparalleled networking opportunities we offer a portfolio of global exhibitions in all major pharma markets throughout the year - take a look at our event calendar for more information.
Together the companies will attempt to overcome "black box" challenges to enable more robust and consistent results for clients
The biologics CDMO says it expects its new 53,000-sq.ft facility will be operational within 18 months
The new the 140,000-sq. ft facility will support commercialisation and industrialisation of viral vectors
The transaction expands the CDMO's GMP biopharmaceutical and vaccine manufacturing capabilities
The LSCC provides an additional 30% in mammalian large-scale capacity for the company's own pipeline and for third parties
By providing AAV process development, scale up and cGMP manufacturing services, Forge hopes to bolster Solid's gene therapy pipeline
The 1.5 million-sq. ft Switzerland-based facility is part of the company's strategic partnership with CSL Limited
Quantum computing technology uses quantum systems called “qubits”. They work with non-binary values, unlike classical computing which uses only bits with values of 0 or 1, and can overlap each other and act as a group. The result is a ...
Position your company at the heart of the global Pharma industry with a CPhI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPhI events
An easy-to-use platform with a detailed dashboard showing your leads and performance